TY  - JOUR
AU  - Serrano López, Dolores Remedios
AU  - Ballesteros Papantonakis, María De La Paloma
AU  - Bolas Fernández, Francisco
AU  - Fernandez-García, Raquel
AU  - Walsh, David
AU  - O'Connell, Peter
AU  - Passero, Luis Felipe
AU  - de Jesus, Jessica A.
AU  - Dalastra Laurenti, Marcia
AU  - Dea-Ayuela, Maria Auxiliadora
AU  - Lalatsa, Aikaterini
AU  - Healy, Anne Marie
PY  - 2025
DO  - 10.1021/acs.molpharmaceut.4c01133
UR  - https://hdl.handle.net/20.500.14352/121063
T2  - Molecular Pharmaceutics
AB  - The incidence of visceral leishmaniasis (VL) remains a significant health threat in endemic countries. Fixeddose combination (FDC) of amphotericin B (AmB) and miltefosine (MLT) is a promising strategy for treating VL, but the parenteral administration...
LA  - eng
M2  - 1437
PB  - ACS Publications
KW  - oral delivery
KW  - amphotericin B
KW  - fixed-dose combination
KW  - miltefosine
KW  - coating
KW  - visceral leishmaniasis
TI  - Targeted Oral Fixed-Dose Combination of Amphotericin B‑Miltefosine for Visceral Leishmaniasis
TY  - journal article
VL  - 22
ER  -